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ABSTRACT
Background
Very little longitudinal information is available regarding the performance of T cell-based
tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a
longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in
comparison to the standard tuberculin skin test (TST).
Methods and Findings
In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n¼341) and 18 mo (n¼210)
after recruitment and TSTs at 18 mo (n ¼ 130). We evaluated factors for association with
conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative
contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive
recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0–5.0, p ¼ 0.048) and
negatively associated with bacillus Calmette-Gue ´rin (BCG) vaccination (OR 0.5, 95% CI 0.2–1.0, p
¼0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in
those with a positive recruitment TST (OR 0.3, 95% CI 0.1–0.8, p¼0.014). Between 3 and 18 mo,
35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT
reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all
three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18
mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was
associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4–37.1, p¼0.019); 18 (32.7%)
underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts
diagnosed as having TB were mixed, but suggested higher TST sensitivity.
Conclusions
Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT
reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute
to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M.
tuberculosis infection should be interpreted with caution.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Recent work suggests that a T cell-based assay for
interferon gamma, the enzyme-linked immunosorbent spot
test (ELISPOT), has promise in the diagnosis of Mycobacterium
tuberculosis infection after exposure to a known tuberculosis
(TB) patient [1–3]. However, commercialisation of two T cell-
based tests for the diagnosis of M. tuberculosis infection (T-
Spot.TB by Oxford Immunotec and Quantiferon-TB Gold by
Cellestis) preceded substantial longitudinal assessment of
either test. Apart from two small studies [4,5], longitudinal
assessment of an ELISPOT assay for M. tuberculosis infection
has been conﬁned to studies of TB patients undergoing
treatment. These studies have consistently shown that
signiﬁcant ELISPOT reversion occurs over a treatment
course [6–9]. One longitudinal assessment of the Quantiferon
test with respect to M. tuberculosis infection has been
performed, in India [10].
Longitudinal assessment of T cell-based tests for M.
tuberculosis infection should comprise documentation of the
conversion rate in individuals initially testing negative after
M. tuberculosis exposure, the reversion rate in those initially
testing positive, assessment of factors for association with
each phenomenon, and the relationship between an initial
test result and the future development of disease. A
comparison with the traditional tuberculin skin test (TST)
would be optimal. Therefore we established a large cohort of
consecutively recruited TB patient contacts, conducted
repeated ELISPOT and TSTs, and investigated those sus-
pected of developing TB disease.
Materials and Methods
Participants
TB patients over 15 years of age were recruited consec-
utively from the major government TB clinic in Banjul, The
Gambia, and from the Medical Research Council outpatient’s
clinic, as previously described [2]. Included patients had two
sputum smear samples positive for acid-fast bacilli and with
M. tuberculosis isolated upon culture. Household contacts of
the TB patients were eligible for inclusion in the study if they
were at least 15 years of age. Contacts were interviewed,
examined, and a blood sample taken for ELISPOT and HIV
test. Immediately afterwards they underwent a TST (2
Tuberculin Units [TU], PPD RT23, Statens Serum Institut,
http://www.ssi.dk). They were asked to have a repeat ELISPOT
test at 3 and 18 mo. A ‘‘subcohort’’ of 196 consecutively
recruited contacts, with ELISPOT and TST results from
recruitment, were asked to have a repeat TST at 18 mo as
well. We did not conduct ‘‘two-step’’ TSTs at either recruit-
ment or follow-up.
TST conversion was deﬁned as a positive test ( 10 mm
induration) plus an increase in induration of at least 6 mm
[11]. All TST converters were asked to have a chest x-ray and a
clinical examination. Those able to produce sputum under-
went sputum analysis. Those diagnosed with TB disease were
referred to the National Programme for free treatment and
excluded from further longitudinal analyses. There is no
current practice of preventive anti-TB treatment in The
Gambia. HIV-positive individuals were referred for consid-
eration for free antiretroviral treatment.
The study was approved by The Gambia Government/
Medical Research Council joint Ethics Committee. Written
informed consent was obtained from all study participants.
Laboratory Procedures
Sputum smears were prepared and stained with auramine-
phenol [12] and conﬁrmed by Ziehl-Neelsen. Decontaminated
specimens were inoculated into Lowenstein-Jensen medium
and BACTEC 9000 MB liquid medium for isolation and
identiﬁcation of M. tuberculosis, as previously described [13].
Testing for HIV-1 or HIV-2 infection was by competitive
ELISA (Wellcome Laboratories, Dartford, Kent, UK) and
Western blot (Diagnostics Pasteur, http://www.sanoﬁpasteur.
com), as previously described [14].
The ex-vivo ELISPOT assays for IFNc were performed on
fresh samples onsite as previously described [15]. Pooled
sequential 15-mer peptides, overlapping by 10 amino-acid
residues, of ESAT-6 and CFP-10 proteins (Advanced Bio-
technology Centre, www.imperial.ac.uk/advancedbiotechno-
logycentre) were used as stimulatory antigens at 5 lg/ml. The
positive control was phytohaemagglutinin (Sigma-Aldrich,
http://www.sigmaaldrich.com). All antigens were tested in
duplicate wells. Assays were scored by an ELISPOT counter
(AID-GmbH, http://www.aid-diagnostika.com). Positive test
wells were predeﬁned as containing at least 8 spot-forming
units (SFU) more than negative control wells [16]. For a
positive ESAT-6/CFP-10 result it was necessary for at least one
of the two pools of overlapping peptides to be positive.
Phytohaemagglutinin wells were set to at least 150 SFU/well/2
3 10
5 above negative control wells. Negative control wells
were required to have less than 20 SFU. These criteria are the
same as those we have previously documented and are more
stringent than those recommended for the commercial T-
spot assay [3]. ELISPOT conversion and reversion was deﬁned
as a newly positive test or negative test respectively, plus a
change in the combined ESAT-6 and CFP-10 count (above the
negative control) of at least 6 SFU/well/2310
5 (30 SFU/million
cells). Laboratory staff were blinded as to the characteristics
of the individuals tested.
For molecular subtyping of index case isolates, we
extracted mycobacterial DNA using CTAB and chloroform,
as previously described [17], and assessed its concentration
and purity by spectrophotometry. We performed spoligotyp-
ing using membranes from Isogen Biosciences (http://www.
isogen-lifescience.com), as previously described [18] and
analysed the results with software that we designed using
Matlab software (MathWorks, http://www.mathworks.com).
Data Management and Statistical Analysis
The number of SFU in each ELISPOT well were automati-
cally entered into a database. All other data were entered
using double data entry into an ACCESS database and
checked for errors. Agreement between the qualitative test
results was assessed by the kappa statistic and the signiﬁcance
of the discordance was assessed by McNemar test. Random
effects logistic regression models, taking into account house-
hold clustering, were used to separately assess the relation-
ship between exposure and test conversion and reversion
between recruitment and 3 mo, 3 mo and 18 mo, and
recruitment and 18 mo. All statistical analyses were con-
ducted using Stata software (version 8; Stata Corp, http://www.
stata.com).
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Recruitment Results
We recruited 740 contacts of 177 TB patients (Figure 1).
Four were identiﬁed as coprevalent TB patients, and 558 were
selected for ELISPOT and had TST and ELISPOT results: 165
(29.6%) were ELISPOT positive and TST positive, 58 (10.4%)
were ELISPOT positive and TST negative, 100 (17.9%) were
ELISPOT negative and TST positive, and 235 (42.1%) were
negative by both tests. The agreement between the two tests
was 73% (kappa¼0.43) and there was signiﬁcant discordance
identiﬁed (McNemar test: p , 0.001). Of 554 contacts tested,
15 (2.7%) were HIV positive. Since HIV positivity was not
signiﬁcantly associated with conversion or reversion of either
test, such individuals were not excluded from the analysis.
There were no signiﬁcant differences in the age and sex
characteristics of those contacts with results at recruitment,
3-mo follow-up, or 18-mo follow-up, compared to their
source population.
3-Mo ELISPOT Results
Figure 1 shows the details of the 3-mo follow-up of the 558
contacts with results at recruitment. Of 341 contacts who had
ELISPOT results at 3 mo, 133 (39%) were ELISPOT positive
and 208 (61%) were ELISPOT negative. Of the initially
negative individuals, 51 (24.6%) had ELISPOT conversion
(Table 1), which was more likely in those who were TST test
positive at recruitment (odds ratio [OR] 2.2, 95% conﬁdence
Figure 1. Study Profile: Recruitment and 3-Mo ELISPOT Conversion and Reversion
doi:10.1371/journal.pmed.0040192.g001
Table 1. Evaluation of Possible Factors Associated with ELISPOT Test Conversion at 3 Mo and at 18 Mo in TB Patient Contacts
Risk Factor Category 3-Mo Conversion (Total n ¼ 207) 3- to 18-Mo Conversion (Total n ¼ 132)
% (n) OR
(95% CI)
p-Value, Adjusted
OR (95% CI)
p-Value % (n) OR
(95% CI)
p-Value Adjusted
OR (95% CI)
p-Value
Sleep proximity Different house 17.3 (13) 1.0 1.0 21.3 (10) 1.0
Different room 28.4 (25) 1.9 (0.8–4.4) 2.0 (0.8–4.6) 32.3 (20) 1.6 (0.4–6.2)
Same room 29.6 (13) 1.9 (0.8–5.0) 0.24 1.6 (0.6–4.7) 0.31 21.7 (5) 1.0 (0.2–6.3) 0.77
Age (y) 15–20 19.4 (14) 1.0 17.4 (8) 1.0 1.0
21–30 26.5 (18) 1.7 (0.7–4.0) 37.2 (16) 4.3 (1.0–17.5) 3.1 (0.7–12.9)
.30 27.7 (18) 1.7 (0.7–4.0) 0.43 25.6 (11) 1.7 (0.4–7.5) 0.13 1.4 (0.3–5.9) 0.27
Gender Female 21.2 (24) 1.0 1.0 23.1 (18) 1.0
Male 28.7 (27) 1.5 (0.7–3.1) 0.23 1.6 (0.8–3.3) 0.18 31.5 (17) 2.1 (0.6–7.5) 0.27
Recruitment TST Negative 19.9 (29) 1.0 1.0 20.9 (18) 1.0 1.0
Positive 36.1 (22) 2.4 (1.2–5.2) 0.020 2.2 (1.0–5.0) 0.048 37.0 (17) 2.9 (0.8–10.4) 0.10 1.8 (0.5–6.7) 0.39
Recruitment
ELISPOT test
Negative - —— — — 18.9 (17) 1.0 1.0
Positive - —— — — 42.9 (18) 4.5 (1.3–15.6) 0.02 3.7 (1.0–14.1) 0.051
BCG scar Absent/
uncertain
28.3 (32) 1.0 1.0 29.6 (21) 1.0
Present 20.2 (19) 0.6 (0.3–1.3) 0.18 0.5 (0.2–1.0) 0.060 23.0 (14) 0.7 (0.2–2.2) 0.55
doi:10.1371/journal.pmed.0040192.t001
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Longitudinal Evaluation of ELISPOT Testinterval [CI] 1.0–5.0, p¼0.048) and was less likely in those with
a BCG scar (OR 0.5, 95% CI 0.2–1.0, p¼0.060). Of the initially
positive contacts, 54 (40.2%) underwent ELISPOT reversion,
which was less common if the recruitment TST was positive
(OR 0.3, 95% CI 0.1–0.8, p ¼ 0.014); no other factors were
found to be associated with ELISPOT reversion at 3 mo. The
median increase in ELISPOT count for those with conversion
was 21 SFU (range 7 to 192; interquartile range [IQR] 15 to 31
SFU). The median decrease in ELISPOT count for those
undergoing reversion was 21 SFU (range 6 to 334; IQR 11 to
33 SFU).
ELISPOT Results between 3 and 18 Mo
Figure 2 shows the details of the 18-mo follow-up of the 341
contacts with ELISPOT results at 3 mo. Two contacts became
TB patients between 3 and 18 mo, and 210 (90%) of the 234
bled for ELISPOT at 18 mo had adequate results for analysis.
Of these 210 contacts, 73 (34.8%) were ELISPOT negative at
all three time points; 36 (17.1%) were positive at all three
time points. Of contacts who were negative by ELISPOT at 3
mo, 35 (26.5%) underwent ELISPOT conversion at 18 mo.
Such conversion was associated with having been initially
positive by ELISPOT at recruitment, although this was of
borderline signiﬁcance (Table 1; adjusted OR 3.7, 95% CI 1.0–
14.1, p ¼ 0.051). Of contacts who were positive at 3 mo, 28
(35.9%) underwent ELISPOT reversion. ELISPOT reversion
decreased with increasing age (Table 2; p¼0.010) and in those
who had been ELISPOT positive at recruitment (Table 2; OR
0.2, 95% CI 0.05–0.8, p ¼ 0.020). The median increase in
ELISPOT count for those with conversion was 18 SFU (range
6 to 132; IQR 12 to 29 SFU). The median decrease in
ELISPOT count for those undergoing reversion was 20 SFU
(range 7 to 142; IQR 12 to 31 SFU).
ELISPOT and TST Results between Recruitment and 18 Mo
Figure 3 shows the details of the follow-up of the 196
consecutively recruited contacts for repeat ELISPOT and
TST at 18 mo. At 18 mo 45 (34.6%) of the contacts, with
complete results at 18 mo, were ELISPOT positive and TST
positive, nine (6.9%) were ELISPOT positive and TST
negative, 43 (33.1%) were TST positive and ELISPOT
negative, and 33 (25.4%) were negative by both tests. The
agreement between the two tests was 60% (kappa¼0.25) and
signiﬁcant discordance was identiﬁed (McNemar test: p ,
0.001).
Of the 75 contacts who were initially ELISPOT negative
and had complete results at follow-up, 20 (27%) had
ELISPOT conversion and none of the factors considered
were associated (Table 3). Of the 74 contacts who were
initially TST negative and had complete results at follow-up,
37 (50%) had TST conversion, which was more likely to occur
in those who had been ELISPOT positive at recruitment
(Table 3; OR 7.2, 95% CI 1.4–37.1, p¼0.019). There was little
difference in agreement between ELISPOT and TST con-
version, when two alternative deﬁnitions for conversion for
each test were assessed against each other (Table 4). Of 55
ELISPOT-positive contacts, 18 (32.7%) underwent ELISPOT
reversion. Of the 56 TST-positive contacts, only ﬁve (8.9%)
underwent TST reversion. None of the factors considered
were found to be associated with either ELISPOT or TST
reversion (Table 5). The median increase in ELISPOT count
for those with ELISPOT conversion was 18 SFU (range 6 to
132; IQR 11 to 33 SFU). The median increase in induration
Figure 2. Study Profile: 3-Mo and 18-Mo ELISPOT Results
doi:10.1371/journal.pmed.0040192.g002
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Longitudinal Evaluation of ELISPOT Testfor those with TST conversion was 15mm (range 7 to 27; IQR
12 to 17 SFU). The median decrease in ELISPOT count for
those with ELISPOT reversion was 19 SFU (range 7 to 340;
IQR 12 to 31 SFU). The median decrease in induration for
those with TST reversion was 14 mm (range 8 to 23 mm).
Of the 56 contacts who were initially negative by both tests,
6/16 (37.5%) ELISPOT converters did not undergo TST
conversion. All six had 0 mm of induration at both time
points and their median ELISPOT count increase was 22 SFU
(range 18 to 133 SFU). Similarly, 13/23 (56.5%) TST
converters did not undergo ELISPOT conversion: their
median recruitment ELISPOT count was 3 SFU (range 0 to
7 SFU) and their median change in count was 3 SFU (range 3
to 5 SFU). Ten contacts, initially negative by both tests, had
conversion of both: the median increase in induration was
16mm (range 6 to 27 mm) and the median increase in
ELISPOT count was 18 SFU (range 7 to 76 SFU). Five of the
130 contacts with TST and ELISPOT results at recruitment
and 18 mo had TST conversion and ELISPOT reversion: the
median increase in induration was 14 mm (range 10 to 19
mm), and the median drop in ELISPOT count was 19 SFU
(range 9 to 25 SFU).
Identification of Secondary TB Patients
Among 665 contacts with complete follow-up information
regarding symptoms over the 18 mo period, 13 TB patients
were identiﬁed: ﬁve at recruitment, four by 4 mo, two
between 4 and 18 mo, and two after 18 mo (Table 6). All ﬁve
diagnosed at recruitment were TST positive, and three were
ELISPOT positive. Of the four individuals diagnosed by 4 mo,
one had been negative by both ELISPOT and TST at
recruitment and did not have TST conversion (no ELISPOT
result at 3 mo), one was positive on both tests at recruitment,
and two were positive on TST but negative by ELISPOT at
recruitment; one of these underwent ELISPOT conversion.
Of the two individuals diagnosed at 14 mo, one was negative
by both tests at recruitment and 3 mo, the other was positive
by TST at recruitment and underwent ELISPOT conversion
at 3 mo. Of the two patients diagnosed after 18 mo, one was
ELISPOT positive at recruitment and TST negative and later
had TST conversion, the other was persistently ELISPOT
negative but had TST conversion at 18 mo. All those with a
negative ELISPOT test had a count of at least 3 SFU below the
cut-off for a positive result. Six patients had both a cultured
isolate and the isolate of their respective index case available;
three had identical spoligotype patterns and three were
different.
Discussion
In this study of over 1,100 individual ELISPOT test results
and nearly 800 TST results, we have shown that ELISPOT
conversion and reversion occur after an initial post-M.
tuberculosis exposure screening process. In contrast to the
low rate of TST reversion over time, ELISPOT reversion
occurred in 40% of ELISPOT-positive individuals at 3 mo,
and in 36% of individuals between 3 and 18 mo. Conversely,
the ELISPOT conversion rate was 27% at 18 mo compared to
a TST conversion rate of 50% over the same time period.
Conversion and reversion of the ELISPOT test are associated
with identiﬁable risk factors that differ from those associated
with TST conversion and reversion. These results provide
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Longitudinal Evaluation of ELISPOT Testnew insights into the possible niche for ELISPOT in the
diagnosis of latent M. tuberculosis infection and TB disease.
To our knowledge, only two small longitudinal studies of
ELISPOT results in TB patient contacts have been reported.
Ewer et al. [4] found a signiﬁcant decline in ELISPOT counts
at 18 mo in those who underwent prophylactic treatment, 11
untreated ELISPOT-negative adults had no signiﬁcant change
in count, while seven of 14 untreated ELISPOT-positive
individuals underwent ELISPOT reversion; all seven had
negative TST results at recruitment. The high reversion rate
and association with a negative initial TST are consistent with
the ﬁndings of our study. The lack of ELISPOT conversion
can possibly be explained by the 4-mo time delay in
conducting the initial ELISPOT screen. Wilkinson et al. [5]
showed a signiﬁcant early rise in the ELISPOT count in 33
Heaf test-positive individuals given isoniazid and rifampicin,
then a reduction in count at 3 mo. There were no signiﬁcant
changes in counts in eight individuals who had opted for no
treatment. A longitudinal assessment of the Quantiferon test
conducted in India [10] included follow-up of 216 nursing
and medical students. Overall, nine (24%) of 38 initially test-
positive participants underwent test reversion. Consistent
with our study, the investigators found that initially positive
individuals were more likely to undergo Quantiferon test
reversion if their initial TST was negative. The agreement
between the TST and Quantiferon was higher at both time
points than in our study. Furthermore, in contrast to our
study, all those with TST conversion with at least a 10 mm
Figure 3. Study Profile: Recruitment and 18-Mo ELISPOT and TST Conversion and Reversion
doi:10.1371/journal.pmed.0040192.g003
Table 3. Evaluation of Possible Factors Associated with ELISPOT Test and TST Conversion after 18 Mo in TB Patient Contacts
Risk
Factor
Category 18-Mo ELISPOT Conversion (Total n ¼ 75) 18-Mo TST Conversion (Total n ¼ 74)
% (n) OR
(95% CI)
p-Value,
OR
Adj OR
(95% CI)
p-Value,
Adjusted OR
% (n) OR
(95% CI)
p-Value,
OR
Adj OR
(95% CI)
p-Value,
Adjusted OR
Sleep
proximity
Different house 30.0 (6) 1.0 45.8 (11) 1.0 1.0
Different room 27.9 (12) 0.9 (0.3–2.9) 42.5 (17) 0.9 (0.2–3.4) 0.9 (0.2–3.5)
Same room 16.7 (2) 0.5 (0.1–2.8) 0.69 90.0 (9) 18.7 (1.0–351) 0.11 17.0 (1.0–291.8) 0.10
Age (y) 15–20 18.8 (6) 1.0 1.0 42.9 (12) 1.0
21–30 22.2 (4) 1.2 (0.3–5.1) 1.0 (0.2–4.5) 57.7 (15) 1.4 (0.3–5.9)
.30 40.0 (10) 2.9 (0.9–9.5) 0.18 2.5 (0.7–8.5) 0.26 50.0 (10) 1.2 (0.3–5.4) 0.91
Gender Female 25.0 (11) 1.0 46.5 (20) 1.0 1.0
Male 29.0 (9) 1.2 (0.4–3.4) 0.70 53.3 (16) 2.2 (0.5–9.3) 0.29 2.0 (0.5–8.2) 0.31
Other test at
recruitment
a
Negative 28.6 (16) 1.0 41.1 (23) 1.0 1.0
Positive 21.1 (4) 0.7 (0.2–2.3) 0.52 77.8 (14) 5.8 (1.3–27.0) 0.025 7.2 (1.4–37.1) 0.019
BCG scar Absent/
uncertain
33.3 (12) 1.0 1.0 50 (20) 1.0
Present 20.5 (8) 0.52 (0.2–1.5) 0.21 0.6 (0.2–1.8) 0.35 50 (17) 1.4 (0.3–5.3) 0.67
aFor ELISPOT conversion the ‘‘other test’’ refers to the recruitment TST. For TST conversion, the other test is the ELISPOT at recruitment.
doi:10.1371/journal.pmed.0040192.t003
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Longitudinal Evaluation of ELISPOT Testincrease in induration, had large increases in levels of IFN-c
on Quantiferon assay. It is important to note that there were
several important differences between the Indian study and
ours. For example, one TU was used for the skin test and
individuals were more likely to have ongoing exposure to M.
tuberculosis, being hospital based.
Conversion and reversion of the traditional TST following
BCG vaccination have been reported in a TB-endemic
tropical setting [19]. Although TST reversion would not be
expected after only 3 mo [20], it is an important consid-
eration when interpreting trends in positivity at a population
level. It appears that TST reversion is greatest in the youngest
age groups and after nontuberculous mycobacterial expo-
sure, while the rate of TST conversion gradually increases
with age [21–23]. At both ELISPOT follow-up time points,
those who were in the youngest age group had the highest
ELISPOT reversion rate in our study; this was statistically
signiﬁcant at the 18-mo time point. Therefore, it is important
that a longitudinal assessment of the ELISPOT now be
conducted in children.
That a large proportion of contacts undergo rapid
reversion of the ELISPOT is consistent with the premise that
ELISPOT responses are transient and generally require
continued exposure to antigen to maintain high frequencies.
While some reversion could reﬂect clearance of the organism,
it may simply be a function of the M. tuberculosis life cycle,
whereby the mycobacterium enters a dormant state in which
it may not reliably secrete ESAT-6 and CFP-10, but
preferentially secretes other antigens [24]. Using antigens
preferentially secreted by M. tuberculosis in its dormant phase,
it may prove possible to distinguish those who retain the
infection from those who clear it [25]. It is quite possible,
however, that ESAT-6 and CFP-10 are secreted intermittently
by M. tuberculosis at all stages of its life cycle [26]. Furthermore,
persistence of an ‘‘ELISPOT detectable’’ T cell response may
occur in certain individuals in the absence of direct antigen
stimulation [8]. That ELISPOT reversion between 3 and 18
mo was less likely in those that had previously been ELISPOT
positive is of interest in this regard. Studies are underway in
The Gambia to explore these issues.
ELISPOT and/or TST conversions have several possible
explanations. First, the interval between initial exposure and
TST conversion has been shown to be up to 6 wk after BCG
vaccination [27] and 3–7 wk following known M. tuberculosis
exposure [28]. The corresponding time interval for the
ELISPOT test is not known. It is possible that it is shorter
than that of the TST, as TST conversion at 18 mo was
signiﬁcantly more likely in those who had been ELISPOT
positive at recruitment. However, ELISPOT conversion at 3
mo was slightly more likely in those who had been TST
Table 4. Conversion of the Tuberculin and ELISPOT Tests in Relation to Each Other, According to Different Cut-Offs in Those That Were
Initially Negative by Both Tests (n ¼ 56)
Test Result TST Induration Increase  6 mm TST Induration Increase  10 mm
No Yes Agreement j
b No Yes Agreement j
b
ELISPOT increase
a  6 spots No 27 13 53.8% 0.27 27 13 54.6% 0.21
Yes 6 10 7 9
ELISPOT increase
a  10 spots No 28 17 55.4% 0.12 29 16 56.5% 0.14
Yes 5 6 5 6
For test conversion it was also mandatory to become test positive (see Methods).
aSpot-forming units/200,000 cells.
bKappa statistic.
doi:10.1371/journal.pmed.0040192.t004
Table 5. Evaluation of Possible Factors Associated with ELISPOT or TST Reversion after 18 Mo in TB Patient Contacts
Risk Factor Category 18-Mo ELISPOT Reversion (n ¼ 55) 18-Mo TST Reversion (n ¼ 56)
% (n) OR (95% CI) p-Value % (n) OR (95% CI) p-Value
Sleep proximity Different house 14.3 (2) 1.0 10.0 (1) 1.0
Different room 39.3 (11) 4.5 (0.5–37.6) 6.5 (2) 0.6 (0.1–7.7)
Same room 38.5 (5) 4.3 (0.4–43.0) 0.36 13.3 (2) 1.4 (0.1–17.7) 0.74
Age (y) 15–20 58.3 (7) 1.0 6.3 (1) 1.0
21–30 21.7 (5) 0.2 (0.1–1.0) 6.7 (1) 1.1 (0.1–18.8)
.30 30.0 (6) 0.3 (0.1–1.6) 0.14 12.0 (3) 2.0 (0.2–21.6) 0.77
Gender Female 33.3 (12) 1.0 11.1 (4) 1.0
Male 31.6 (6) 0.8 (0.2–4.2) 0.82 5.0 (1) 0.4 (0.1–4.0) 0.45
Other test at recruitment
a Negative 38.9 (7) 1.0 5.3 (1) 1.0
Positive 29.7 (11) 0.4 (0.1–3.1) 0.41 10.8 (4) 2.2 (0.2–21.0) 0.50
BCG scar Absent/uncertain 31.4 (11) 1.0 12.9 (4) 1.0
Present 35.0 (7) 1.4 (0.3–7.4) 0.68 4.0 (1) 0.3 (0.1–2.7) 0.27
aFor ELISPOT conversion the ‘‘other test’’ refers to the recruitment TST. For TST conversion, the other test is the ELISPOT at recruitment.
doi:10.1371/journal.pmed.0040192.t005
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Longitudinal Evaluation of ELISPOT Testpositive at recruitment. Such a mixed result is consistent with
the secondary case data—one patient had been initially
positive by ELISPOT and negative by TST, becoming positive
by TST later; however for two patients the opposite was true.
Second, it is likely that some contacts become exposed to M.
tuberculosis for a period after their respective index case
begins treatment. Third, it is possible for individuals to be
exposed to an unrecognised case. This is supported by the
fact that three of six ‘‘secondary’’ cases with molecular
subtyping results had an isolate with a different spoligotype
pattern than their respective index case. Finally, the TST is
subject to boosting of waned immunity to tuberculous and
nontuberculous past exposure. Therefore, the difference in
conversion rates at 18 mo (27% for ELISPOT versus 50% for
TST) may be due to a combination of factors: slightly
increased TST sensitivity, different times to positivity, TST
boosting, and early ELISPOT reversion. While 13 of 23 of TST
converters did not undergo ELISPOT conversion, it is of note
that only ten of 16 ELISPOT converters had TST conversion.
It is therefore quite likely that certain individuals with
genuine new M. tuberculosis infection preferentially respond
to one test and not the other.
Our ﬁnding that ELISPOT conversion between 3 and 18
mo was associated with having been positive at recruitment
adds further weight to the argument that ELISPOT reversion
at 3 mo cannot be explained completely by clearance of the
infection. As discussed above, one would expect intermittent
antigen secretion to cause the ELISPOT test to ‘‘switch on,’’
‘‘switch off,’’ and ‘‘switch on’’ again over time.
In this study we found that those with a visible BCG scar
were less likely to undergo ELISPOT conversion. While this
ﬁnding was of borderline statistical signiﬁcance, it is
consistent with the ﬁnding, by Soysal et al. [29], that TB
patient contacts with a BCG scar in Turkey were less likely
than those without to have a positive ELISPOT test. Soysal et
al. argue that this is evidence in favour of the premise that
BCG may protect against new M. tuberculosis infection.
In The Gambia we have used mathematical tools on results
from over 1,000 individuals to identify a cut-off for positivity
of the ELISPOT test [16] of eight spots per well (40 spots/
million cells) above the negative control well when using two
antigens, as opposed to ﬁve or six spots per well that has been
used in some other studies [1]. The criterion we used for TST
conversion was chosen because chance variation in the TST
reading results had been reported to be less than 6 mm of
induration in over 95% of individuals [11,30]. No criteria for
ELISPOT conversion and reversion have been proposed. We
consulted researchers experienced in working with ELISPOT
assays in coming to these criteria and considered variability
between duplicate test wells that we have previously reported
[9]. It is also of note, in this regard, that there was little change
in agreement between the and ELISPOT when we compared
different criteria (Table 5). However, it is important that
further detailed studies are conducted to clearly determine
reproducibility of ELISPOT results.
There are other limitations of this study. First, 25% to 33%
of the contacts were lost to follow-up between the different
time points and a further 5% to 8% of contacts’ samples were
subject to test failure. While we did not ﬁnd any signiﬁcant
differences in the basic characteristics of those followed
versus those lost to follow-up, the study is vulnerable to
unknown sources of bias. Second, in this cohort we did not
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Longitudinal Evaluation of ELISPOT Testhave a TST and ELISPOT comparison at 3 mo. This
comparison would be helpful with respect to understanding
agreement between the two tests, although it is not ideal to
have injection of mycobacterial antigens in between the other
two time points. Third, while our secondary case information
is useful, larger numbers will be required to draw deﬁnitive
conclusions.
The results of this study have important implications for
clinical practice and future research on T cell assays for M.
tuberculosis infection. It is clear that ELISPOT reversion is
much more frequent than TST reversion, and this key
difference will be crucial in the interpretation of both tests
in relation to each other, especially when there is no
particular reference point in time for exposure to M.
tuberculosis. Those using a T cell-based test to screen for M.
tuberculosis infection should be cautious when interpreting a
negative result. It is important that long-term follow-up of
large numbers of case contacts be conducted to identify
enough secondary cases to provide further insights into the
meaning of rapid ELISPOT reversion and of discordant
results. Such studies are underway in The Gambia. It will also
be important to document the rates of ELISPOT conversion
and reversion in children. These studies will help to deﬁne
the ultimate niche for T cell-based tests in relation to TB.
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Longitudinal Evaluation of ELISPOT TestEditors’ Summary
Background. Tuberculosis is a contagious bacterial infection, usually of
t h el u n g s .P e o p l ew i t ha c t i v et u b e r c u l o s i ss p r e a dt h ec a u s a t i v e
bacterium (Mycobacterium tuberculosis) in airborne droplets whenever
they cough or sneeze. Most people exposed to M. tuberculosis in this way
never become ill—their immune system successfully contains the
infection. However, the bacteria remain dormant in the body and can
cause disease years later if host immunity declines because of, for
example, infection with the human immunodeficiency virus (HIV).
Consequently, to control the spread of tuberculosis, individuals who
have been in contact with people with active tuberculosis need to be
tested for infection with M. tuberculosis and treated with antituberculosis
drugs if positive. The standard test for infection is the tuberculin skin test
(TST). In this, bacterial antigens (proteins that the immune system
recognize as foreign) are injected under the skin. The immune system of
infected individuals attacks the antigen and produces a hard swelling at
the injection site. Unfortunately, this test does not detect all M.
tuberculosis infections and an alternative, laboratory-based test has
recently been developed. During M. tuberculosis infections, immune
system cells called T lymphocytes produce interferon gamma. This
protein activates macrophages, immune system cells that kill bacteria.
The ELISPOT (enzyme-linked immunosorbent spot) test measures
interferon gamma production by T lymphocytes.
Why Was This Study Done? Commercial ELISPOT tests are available for
the diagnosis of M. tuberculosis infection, but little is known about how
they perform when used in repeat tests in individuals or whether the TST
or ELISPOT test is better at predicting later development of tuberculosis.
In this study, the researchers investigated these questions in a
longitudinal assessment of the ELISPOT test in Gambians exposed to
active tuberculosis.
What Did the Researchers Do and Find? The researchers recruited
people who had been in contact with active tuberculosis, did ELISPOT
tests and TSTs at recruitment, then repeated the ELISPOT test after three
months and both tests in some participants after 18 months. They
analyzed how often ELISPOT conversion (a change from a negative to a
positive result indicating the development of an active immune
response) and reversion (a change from a positive to a negative result
reflecting clearance of the bacteria or its entry into a dormant state)
occurred, whether the TST results mirrored these changes, and which
characteristics of the participants were associated with conversion or
reversion. A quarter of participants who initially had a negative ELISPOT
result had a positive result at three months, a conversion that was
associated with a positive TST at recruitment. ELISPOT reversion at three
months, by contrast, was associated with an initially negative TST and
occurred in nearly half the participants. However, about a third of the
participants had negative ELISPOT results at all three time points and a
fifth had positive results at all times. Overall, the two tests agreed in 73%
and 60% of the participants at recruitment and at 18 months,
respectively. Finally, among the 13 contacts who developed active
tuberculosis, some were initially positive in both tests but others showed
subsequent conversion in one, both or neither test.
What Do These Findings Mean? These findings indicate that both
ELISPOT conversion and reversion occur after initial screening for M.
tuberculosis infection. In addition, they suggest that the immune system
responses to M. tuberculosis detected by TST and the ELISPOT test occur
over different time scales and so the two tests might differ in their ability
to detect M. tuberculosis infections at different times after exposure to
the bacteria. Because very few contacts developed active tuberculosis,
the findings do not indicate which test best predicts disease develop-
ment after M. tuberculosis infection. Further studies are needed to
provide this information and to unravel the complexities of ELISPOT
conversion and reversion after exposure to M. tuberculosis. Importantly,
however, the high frequency of ELISPOT reversion seen in this study
suggests that a negative ELISPOT result may not reflect a lack of infection
after exposure to M. tuberculosis and must, therefore, be interpreted with
caution.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040192.
  The US Centers for Disease Control and Prevention provide fact sheets
from the Division of Tuberculosis Elimination about tuberculosis, its
testing and diagnosis, and its treatment
  MedlinePlus Encyclopedia contains information on tuberculosis and
the tuberculin skin test (in English and Spanish)
  The American Lung Association offers fact sheets on tuberculosis and
on the tuberculin skin test
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